Clinical trials: CD7+ Lymphoma
T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma
Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell Malignances
This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of non-gene edited anti-CD7 CAR (also called anti-CD7 CAR) T cells in patients with relapsed and/or refractory T…
- Conditions
- T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma, T-cell Non-Hodgkin Lymphoma
- Trial name
- NCT04934774
- Testing
- CD7 CAR T cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- iCell Gene Therapeutics
Lymphoblastic Lymphoma, T-Cell Lymphoblastic Leukemia/Lymphoma
A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)
This is a Phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of BEAM-201 in patients with relapsed/refractory T-ALL or T-LL.
- Conditions
- Lymphoblastic Lymphoma, T-Cell Lymphoblastic Leukemia/Lymphoma, Lymphoblastic Leukemia
- Trial name
- NCT05885464
- Testing
- BEAM-201
- Where
- 10 sites in United States
- Volunteers
- 5 people
- Sponsor
- Beam Therapeutics Inc.
T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
CD7-CAR-T Cells in Pediatric Relapsed/Refractory CD7+ T-ALL/LL
The main purpose of this study is to evaluate the safety, to establish the recommended dose, and to evaluate the antitumor effect of CD7-CART01 in pediatric patients with relapsed or refractory (R/R) T-cell acute lymphoblastic…
- Trial name
- CD7-CAR01 (NCT06064903)
- Testing
- CD7-CART01
- Where
- Italy
- Volunteers
- 26 people
- Sponsor
- Bambino Gesù Hospital and Research Institute
T Acute Lymphoblastic Leukemia, T-lymphoblastic Lymphoma
RD13-01 for Patients With r/r CD7+ T-ALL/T-LBL
This study is designed to explore the safety of RD13-01 for patients with CD7+ relapsed and/or refractory T cell acute lymphoblastic leukemia or lymphoblastic lymphoma.
- Trial name
- NCT04620655
- Testing
- RD13-01 cell infusion
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Min Xiang
T Lymphoblastic Leukemia/Lymphoma, Extramedullary NK-T-cell Lymphoma, Nasal Type
CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Label Study
Phase I was a single arm, open label, dose increasing study to explore the safety, tolerance and Cytodynamic characteristics of the drug, and to preliminarily observe the efficacy of the study drug in relapsed / refractory CD7…
- Conditions
- T Lymphoblastic Leukemia/Lymphoma, Extramedullary NK-T-cell Lymphoma, Nasal Type, Peripheral T-cell Lymphoma, Nonspecific, Angioimmunoblastic T-cell Lymphoma
- Trial name
- NCT04480788
- Testing
- T cell injection targeting CD7 chimeric antigen receptor
- Where
- China
- Volunteers
- 9 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
T-Cell Acute Lymphoblastic Leukemia/Lymphoma
Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma
This will be a Phase 1, open-label study to evaluate the safety and efficacy of BEAM-201 in patients with R/R T-ALL or T-LLy. BEAM-201 is an allogeneic anti-CD7 CART therapy.
- Trial name
- 24CT015 (NCT06934382)
- Testing
- Allogeneic anti-CD7 CAR-T cells (BEAM-201)
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Stephan Grupp MD PhD
T-lymphoblastic Lymphoma, NK/T Cell Lymphoma
CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia
This study is designed to explore the safety and efficacy of CD7 CAR-T Cells for patients with relapse/refractory CD7+ NK/T cell lymphoma ,T-lymphoblastic lymphoma and Acute Lymphocytic Leukemia.
- Conditions
- T-lymphoblastic Lymphoma, NK/T Cell Lymphoma, Acute Lymphocytic Leukemia
- Trial name
- NCT04004637
- Testing
- CD7 CAR-T cells infusion
- Where
- China
- Volunteers
- 10 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma
Universal 4SCAR7U Targeting CD7-positive Malignancies
The purpose of this clinical trial is to assess the feasibility, safety and efficacy of universal CAR T cells based on 4SCAR7U design against CD7-positive hematological malignancies using CD7 specific universal CAR T cells.
- Conditions
- T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma, Acute Myeloid Leukemia, NK Cell Lymphoma
- Trial name
- NCT05995028
- Testing
- Universal CD7-specific CAR gene-engineered T cells
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
CD7+ Acute Leukemia, CD7+ Lymphoma
Clinical Trial for the Safety and Efficacy of Anti-CD7 CAR-T Cell Therapy for Patients With Relapsed or Refractory CD7 Positive Hematological Malignancy
This is a prospective, open-label, single-center clinical trial. This study will evaluate the safety and efficacy of anti-CD7 CAR-T cells in the treatment of relapsed or refractory CD7 positive T-ALL/LBL, T-NHL and AML.
- Trial name
- NCT04599556
- Testing
- anti-CD7 CAR-T
- Where
- China
- Volunteers
- 81 people
- Sponsor
- Zhejiang University
T-Cell Non-Hodgkin Lymphoma, T-cell Lymphoma (PTCL and CTCL)
CD7 CAR T-Cell Therapy for r/r T-cell Lymphomas
This is a multi-center, open-label, non-randomized, single-arm clinical trial. Refractory/relapse T-NHL patients are treated with autologous and allogeneic CD7 CAR T-cell therapy.
- Trial name
- NCT06925464
- Testing
- CD7 CAR-T cells infusion
- Where
- 4 sites in China
- Volunteers
- 36 people
- Sponsor
- Beijing GoBroad Hospital
T-Cell Acute Lymphocytic Leukemia
A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ Lymphoma
This study is a single arm, non blind, randomized, single center study aimed at evaluating the safety, pharmacokinetic characteristics, and preliminary efficacy of CD7 CAR-T cell injection in r/r T-ALL/LBL subjects.
- Trial name
- NCT05909527
- Testing
- CD7 CAR-T
- Where
- China
- Sponsor
- Guangzhou Bio-gene Technology Co., Ltd
T Lymphoblastic Leukemia/Lymphoma, Mixed Phenotype Acute Leukemia
Humanized CD7 CAR T-cell Therapy for r/r CD7+ Acute Leukemia
This is a prospective,open-label, single center and single arm phase 1/2 study to evaluate the efficacy and safety of T cells expressing humanized CD7 chimeric antigen receptors treatment for patients with refractory/relapsed CD7…
- Conditions
- T Lymphoblastic Leukemia/Lymphoma, Mixed Phenotype Acute Leukemia, Acute Myeloid Leukemia
- Trial name
- NCT04762485
- Testing
- Humanized CD7 CAR-T cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Leukemia
CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia
The objective of this study is to assess the safety and efficacy of anti-CD7 CAR T-cells in patients with refractory or relapsed T-lineage acute lymphoblastic leukemia (T-ALL).
- Conditions
- Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Leukemia, Lymphoblastic Leukemia, Acute Adult, Lymphoblastic Leukemia in Children
- Trial name
- NCT05043571
- Testing
- CAR T-cell therapy
- Where
- Singapore
- Volunteers
- 20 people
- Sponsor
- National University Hospital, Singapore
Peripheral T Cell Lymphoma
Clinical Study of CD7 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory CD7-positive Peripheral T Cell Lymphoma
Despite the use of monoclonal antibodies, checkpoint inhibitors, and bispecific T cell adapters (BiTE) Immunotherapies such as chimeric antigen receptor (CAR) T cells have completely changed the treatment methods of various…
- Trial name
- NCT05979792
- Testing
- CAR-T Therapy
- Where
- 8 sites in China
- Volunteers
- 35 people
- Sponsor
- Zhao Weili
T-ALL
The Safety and Efficacy of VGO-Cs01p in Patients With CD7-positive Relapsed/Refractory Acute T-lymphoblastic Leukemia
To learn if the VGO-Cs01p can help to control CD7-positive relapsed/refractory acute T-lymphoblastic leukemia (R/R T-ALL) in children.
- Trial name
- NCT06849401
- Testing
- VGO-Cs01p
- Volunteers
- 9 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
T Lymphoblastic Leukemia/Lymphoma, T-cell Acute Lymphoblastic Leukemia
Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies
The purpose of this study is to evaluate the safety and efficacy of CAR T cell treatment targeting CD7 in patients with relapsed or refractory CD7 positive T-cell hematological maliganacies
- Conditions
- T Lymphoblastic Leukemia/Lymphoma, T-cell Acute Lymphoblastic Leukemia, Peripheral T Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma
- Trial name
- NCT05290155
- Testing
- anti-CD7 CAR-T cells
- Where
- China
- Volunteers
- 14 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
T-cell Acute Lymphoblastic Lymphoma, T-non-Hodgkin Lymphoma
Novel Unedited Allo Cell Therapy For High Risk T-Cell Malignancies Using CD7-Specific Car T Cells
Patients eligible for this study have a type of blood cancer called T-cell leukemia or lymphoma (lymph gland cancer). The body has different ways of fighting infection and disease.
- Conditions
- T-cell Acute Lymphoblastic Lymphoma, T-non-Hodgkin Lymphoma, T-cell Acute Lymphoblastic Leukemia
- Trial name
- NCT07220993
- Testing
- CD7.CAR/28zeta T Cells
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Baylor College of Medicine
T-Cell Non-Hodgkin Lymphoma, Acute Myeloid Leukemia
Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies
Effective treatment options for relapsed/refractory acute myeloid leukemia (AML) and T-cell non-Hodgkin lymphoma (T-NHL) represent a significant unmet medical need.
- Conditions
- T-Cell Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Angioimmunoblastic T-cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma
- Trial name
- NCT05377827
- Testing
- WU-CART-007
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Washington University School of Medicine
Acute Myeloid Leukemia (AML), T Lymphoblastic Leukemia/Lymphoma
uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies
The aim of this study was to evaluate the safety and efficacy of universal CD7 CART (uCD7 CART) cells in the treatment of patients with relapsed/refractory CD7-positive hematologic malignancies.
- Trial name
- NCT07109518
- Testing
- uCD7 CART
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
T-cell Leukemia/Lymphoma, Refractory T Lymphoblastic Leukemia/Lymphoma
Multi-centers, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Donor-Derived CD7 CAR T Cells in Subjects With Relapsed or Refractory T-cell Leukemia/Lymphoma
This is a multi-centers, single-arm, open label, Phase 2 clinical trial to evaluate the efficacy and safety of CD7 CAR T cells in subjects with relapsed or refractory T-cell leukemia/lymphoma. Seventy subjects will be enrolled.
- Conditions
- T-cell Leukemia/Lymphoma, Refractory T Lymphoblastic Leukemia/Lymphoma, Relapse/Recurrence
- Trial name
- NCT04689659
- Testing
- chimeric antigen receptor T cell treatment
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Beijing Boren Hospital